Why the study?
Endogenous cardiac regeneration capacity is limited and exogenous cell-based treatments show modest efficacy, making identification and manipulation of the adult cardiac stem cell niche critical to boost clinical efficacy.
Understanding the vascular niche of adult cardiac progenitor cells, particularly Bmi1+ cells, may guide new approaches to boost clinical efficacy in cardiac regeneration therapies.
Limited adult cardiac regeneration capacity and modest cell therapy efficacy warrant clinical caution; leaves open combined approaches for future trials.
Research on cardiac progenitor cell populations has generated expectations about their potential for cardiac regeneration capacity after acute myocardial infarction and during physiological aging; however, the endogenous capacity of the adult mammalian heart is limited. The modest efficacy of exogenous cell-based treatments can guide the development of new approaches that, alone or in combination, can be applied to boost clinical efficacy. The identification and manipulation of the adult stem cell environment, termed niche, will be critical for providing new evidence on adult stem cell populations and improving stem-cell-based therapies. Here, we review and discuss the state of our understanding of the interaction of adult cardiac progenitor cells with other cardiac cell populations, with a focus on the description of the B-CPC progenitor population (Bmi1+ cardiac progenitor cell), which is a strong candidate progenitor for all main cardiac cell lineages, both in the steady state and after cardiac damage. The set of all interactions should be able to define the vascular cardiac stem cell niche, which is associated with low oxidative stress domains in vasculature, and whose manipulation would offer new hope in the cardiac regeneration field.
No takes yet. Share an insight, caveat, or question.
Herrero et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: